| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JAC/DKW587 |
| P698 | PubMed publication ID | 28137941 |
| P50 | author | Françoise Van Bambeke | Q37828419 |
| Julien M Buyck | Q83178861 | ||
| P2093 | author name string | P M Tulkens | |
| W W Nichols | |||
| K M Krause | |||
| G G Muccioli | |||
| C Luyckx | |||
| P2860 | cites work | Membrane flow during pinocytosis. A stereologic analysis | Q24682143 |
| Avibactam and Class C -Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance | Q27684678 | ||
| In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters | Q34134689 | ||
| Commentary. Lysosomotropic agents | Q34214505 | ||
| Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination | Q34325573 | ||
| Inhibition of macrophage phagocytosis by Pseudomonas aeruginosa rhamnolipids in vitro and in vivo | Q34384103 | ||
| Mechanisms of antimicrobial resistance in Gram-negative bacilli. | Q35935319 | ||
| Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection | Q36439179 | ||
| Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. | Q36785824 | ||
| In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). | Q37120019 | ||
| Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus | Q37204106 | ||
| Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. | Q38325959 | ||
| A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens | Q38615904 | ||
| The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam | Q38850240 | ||
| The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts | Q39184496 | ||
| Recurrent Pseudomonas Infection Associated with Neutrophil Dysfunction | Q39636840 | ||
| Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa | Q39882644 | ||
| Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus | Q40216245 | ||
| In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms | Q40702364 | ||
| In Vitro Models for the Study of the Intracellular Activity of Antibiotics. | Q40952390 | ||
| Cousins, siblings, or copies: the genomics of recurrent Staphylococcus aureus infections in chronic rhinosinusitis | Q41720698 | ||
| In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy | Q42868287 | ||
| Bacterial distribution in lung parenchyma early after pulmonary infection with Pseudomonas aeruginosa. | Q43789151 | ||
| Validation of carbapenemase and extended-spectrum β-lactamase multiplex endpoint PCR assays according to ISO 15189. | Q43991437 | ||
| Impairment of growth of Listeria monocytogenes in THP-1 macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-alpha and nitric oxide | Q44896081 | ||
| In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor | Q44978552 | ||
| NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases | Q46438783 | ||
| Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value | Q46885882 | ||
| Community-acquired lobar pneumonia caused by Pseudomonas aeruginosa infection in Japan: a case report with histological and immunohistochemical examination. | Q51719782 | ||
| Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. | Q54409613 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| Pseudomonas aeruginosa | Q31856 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1400-1409 | |
| P577 | publication date | 2017-01-30 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa | |
| P478 | volume | 72 |
Search more.